Table 2.
PCR-uncorrected and PCR-adjusted days 14 and 28 treatment outcomes according to study participant ages.
| Age (year) | ASAQ N (%) | AL N (%) | ||||||
|---|---|---|---|---|---|---|---|---|
| [2–5[ | [5–15[ | [15–63] | Total | [2–5[ | [5–15[ | [15–63] | Total | |
| PCR-uncorrected day 14 cure rates | ||||||||
| ACPR | 69/69 (100) | 57/57 (100) | 17/17 (100) | 143/143 (100) | 61/62 (98.4) | 73/73 (100) | 11/11 (100) | 145/146 (99.3) |
| ETF | 0/69 (0) | 0/57 (0) | 0/17 (0) | 0/143 (0) | 1/62 (1.6) | 0/73 (0) | 0/11 (0) | 1/146 (0.7) |
| LCF | 0/69 (0) | 0/57 (0) | 0/17 (0) | 0/143 (0) | 0/62 (0) | 0/73 (0) | 0/11 (0) | 0/146 (0) |
|
| ||||||||
| PCR-uncorrected day 28 cure rates | ||||||||
| ACPR | 68/69 (98.5) | 57/57 (100) | 17/17 (100) | 142/143 (99.3) | 59/62 (95.2) | 68/73 (93.2) | 11/11 (100) | 138/146 (94.5) |
| ETF | 0/69 (0) | 0/57 (0) | 0/17 (0) | 0/143 (0) | 1/62 (1.6) | 0/73 (0) | 0/11 (0) | 1/146 (0.7) |
| LCF | 1/69 (1.4) | 0/57 (0) | 0/17 (0) | 1/143 (0.7) | 2/62 (3.2) | 5/73 (6.8) | 0/11 (0) | 7/146 (4.8) |
|
| ||||||||
| PCR-corrected day 28 cure rates | ||||||||
| ACPR | 68/69 (98.6) | 57/57 (100) | 17/17 (100) | 142/143 (99.3) | 61/62 (98.4) | 73/73 (100) | 11/11 (100) | 145/146 (99.3) |
| ETF | 0/69 (0) | 0/57 (0) | 0/17 (0) | 0/143 (0) | 1/62 (1.6) | 0/73 (0) | 0/11 (0) | 1/146 (0.7) |
| LCF | 1/69 (1.4) | 0/57 (0) | 0/17 (0) | 1/143 (0.7) | 0/62 (0) | 0/73 (0) | 0/11 (0) | 0/146 (0) |